Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Avastin’s Orphan Status Withdrawn for Pleural Mesothelioma
June 6, 2017
- MEXT to Consider Company Payment Probe for Private Univ. Hospitals: Official
June 5, 2017
- Inject Intensive Resources for Healthy Lifespan Extension: Honebuto Draft
June 5, 2017
- Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
- MHLW Mulling to Add Clinical Trial Data for Generic Labels
June 2, 2017
- 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
- 3rd Sakigake Invitation for Drugs Slated for This Autumn: MHLW
June 2, 2017
- Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
- MHLW Proposes Thresholds for 5-Scale Cost-Effectiveness Ratings: Chuikyo
June 1, 2017
- Chuikyo Members Oppose Reference Pricing System for LLPs
June 1, 2017
- Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
- MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
May 31, 2017
- PhRMA Calls for Expedited Discussions on Inclusion of Vaccines in Public Vaccination Programs
May 31, 2017
- MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
May 31, 2017
- MHLW Orders Label Revisions for Pneumovax NP, 3 Other Products
May 31, 2017
- Lyrica OD Tablets, Other New Dosage Forms to Join NHI Price List on May 31
May 30, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Nusinersen, Tenelia-Canaglu Combo Up for MHLW Panel Review on June 9
May 29, 2017
- Off-Year Revision of NHI Prices “Should Be as Restricted as Possible”: LDP Lawmakers
May 29, 2017
- MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…